Related Experiment Video
Updated: Jun 12, 2026
Isolation of Myeloid Dendritic Cells and Epithelial Cells from Human Thymus
Published on: September 19, 2013
Analysis of peripheral blood dendritic cell subtypes in thymomatous MG
1Department of Thoracic Surgery, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.
Insights
Peripheral blood dendritic cell precursors (pDC) are significantly lower in patients with thymomatous myasthenia gravis (MG). These pDC levels may serve as a disease progression marker for thymomatous MG.
Area of Science:
- Immunology
- Cell Biology
Background:
- Myasthenia gravis (MG) is an autoimmune disorder often associated with thymoma.
- Dendritic cell precursors (pDC) play a crucial role in immune regulation.
Purpose of the Study:
- To quantify monocyte-derived dendritic cell precursors (pDC1) and plasmacytoid dendritic cell precursors (pDC2) in peripheral blood mononuclear cells (PBMC) of patients with thymomatous MG.
- To evaluate the pDC1/pDC2 ratio in these patients.
- To assess the impact of treatment on pDC levels.
Main Methods:
- Utilized three-colour monoclonal antibody labelling technology.
- Analyzed PBMCs from 18 patients with myasthenia gravis (MG), 9 thymomatous patients without MG, and 15 healthy controls.
- Compared pDC counts and ratios before and after treatment.
Main Results:
- Patients with thymomatous generalized MG showed significantly lower pDC and pDC subset counts compared to thymomatous controls, both pre- and post-treatment.
- Following treatment, both generalized and ocular MG patients had reduced pDC numbers compared to thymomatous controls.
- No significant differences in the pDC1/pDC2 ratio were observed among the groups.
Conclusions:
- Peripheral blood pDC levels are significantly reduced in thymomatous MG patients.
- Decreased pDC counts were observed post-thymectomy.
- Peripheral blood pDC levels show potential as a biomarker for tracking thymomatous MG disease progression.
Abstract:
The object of this work was to measure the levels of monocyte-derived dendritic cell precursors (pDC1) and plasmacytoid dendritic cell precursors (pDC2) in peripheral blood mononuclear cells (PBMC) of patients with thymomatous MG and to assess the ratio of pDC1/pDC2 in these patients. Three-colour monoclonal antibody labelling technology was used to detect the cell counts and ratio of pDC1 and pDC2 in PBMCs of 18 patients with myasthenia gravis (MG), nine thymomatous patients without MG, and 15 normal controls. The number of pDC and pDC subsets in peripheral blood of patients with thymomatous generalized MG was significantly lower than that in thymomatous controls before and after the treatment. After the treatment, patients with both generalized MG and ocular MG had significantly lower number of pDC compared with thymomatous controls. We found no significant differences in pDC1/pDC2 ratio among groups. Before the extended thymomatous treatment, the number of pDC in patients with generalized MG was significantly lower than that in patients with ocular MG (P < 0.05). The counts of peripheral blood pDC and pDC subsets of patients with thymomatous MG were significantly lower 1 week after extended thymectomy. The counts of pDC and pDC subsets decreased in generalized thymomatous MG, and the patients with generalized MG had lower pDC counts than the patients with ocular MG before the treatment. Treatment resulted in decreased counts of pDC and pDC subsets in thymomatous MG. We suggest that the level of peripheral blood pDC can be used as a marker to define the progress of the disease.
More Related Videos
06:09Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
Published on: June 22, 2016
08:31Characterization of Human Monocyte-derived Dendritic Cells by Imaging Flow Cytometry: A Comparison between Two Monocyte Isolation Protocols
Published on: October 18, 2016